%0 Journal Article
%T Serum biomarkers in patients with drug-resistant epilepsy: a proteomics-based analysis.
%A Ma M
%A Cheng Y
%A Hou X
%A Li Z
%A Wang M
%A Ma B
%A Cheng Q
%A Ding Z
%A Feng H
%J Front Neurol
%V 15
%N 0
%D 2024
%M 38585359
%F 4.086
%R 10.3389/fneur.2024.1383023
%X <B>UNASSIGNED: </B>To investigate the serum biomarkers in patients with drug-resistant epilepsy (DRE).<BR><B>UNASSIGNED: </B>A total of 9 DRE patients and 9 controls were enrolled. Serum from DRE patients was prospectively collected and analyzed for potential serum biomarkers using TMT18-labeled proteomics. After fine quality control, bioinformatics analysis was conducted to find differentially expressed proteins. Pathway enrichment analysis identified some biological features shared by differential proteins. Protein-protein interaction (PPI) network analysis was further performed to discover the core proteins.<BR><B>UNASSIGNED: </B>A total of 117 serum differential proteins were found in our study, of which 44 were revised upwards and 73 downwards. The up-regulated proteins mainly include UGGT2, PDIA4, SEMG1, KIAA1191, CCT7 etc. and the down-regulated proteins mainly include ROR1, NIF3L1, ITIH4, CFP, COL11A2 etc. Pathway enrichment analysis identified that the upregulated proteins were mainly enriched in processes such as immune response, extracellular exosome, serine-type endopeptidase activity and complement and coagulation cascades, and the down-regulated proteins were enriched in signal transduction, extracellular exosome, zinc/calcium ion binding and metabolic pathways. PPI network analysis revealed that the core proteins nodes include PRDX6, CAT, PRDX2, SOD1, PARK7, GSR, TXN, ANXA1, HINT1, and S100A8 etc.<BR><B>UNASSIGNED: </B>The discovery of these differential proteins enriched our understanding of serum biomarkers in patients with DRE and potentially provides guidance for future targeted therapy.